← All Amneal Pharmaceuticals, INC filings

Amneal Pharmaceuticals, INC Form 4 insider transactions

NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals Director Alva Emily Peterson Acquires 40,258 Restricted Stock Units
Director Alva Emily Peterson of Amneal Pharmaceuticals acquired 40,258 restricted stock units on May 2, 2024, according to a recent SEC filing.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals Director Paul M. Meister Acquires 56,361 Restricted Stock Units
Director Paul M. Meister reports acquisition of 56,361 restricted stock units in Amneal Pharmaceuticals, Inc.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals Executive Vice President Tasos Konidaris Reports Stock Transactions
Executive Vice President and CFO of Amneal Pharmaceuticals, Tasos Konidaris, reports the vesting of restricted stock units and subsequent tax withholding.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals Co-CEO Chintu Patel Reports Stock Unit Grants in Form 4 Filing
Co-CEO of Amneal Pharmaceuticals, Chintu Patel, reports the acquisition of restricted stock units and performance-based restricted stock units in a recent SEC Form 4 filing.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals' President & Co-CEO, Chirag K. Patel, Reports Stock Unit Grants
Chirag K. Patel, President & Co-CEO of Amneal Pharmaceuticals, reports the acquisition of restricted stock units and performance-based restricted stock units.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals Executive Vice President Tasos Konidaris Reports Changes in Beneficial Ownership
Executive Vice President and CFO of Amneal Pharmaceuticals, Tasos Konidaris, reports transactions involving Class A Common Stock and Restricted Stock Units.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals Executive Jason B. Daly Reports Stock Transactions
Jason B. Daly, SVP, Chief Legal Officer of Amneal Pharmaceuticals, reports acquisition and disposal of Class A Common Stock and Restricted Stock Units.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals Executive Vice President Andrew Boyer Reports Stock Transactions
Executive Vice President Andrew Boyer reports acquisition and disposal of Amneal Pharmaceuticals Class A Common Stock and Restricted Stock Units.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals Executive Vice President Nikita Shah Reports Stock Transactions
Executive Vice President Nikita Shah reports acquisition and disposal of Amneal Pharmaceuticals (AMRX) Class A Common Stock and Restricted Stock Units.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals Executive Vice President Andrew Boyer Reports Stock Transactions
Executive Vice President Andrew Boyer of Amneal Pharmaceuticals reports the vesting of restricted stock units and subsequent stock transactions.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
Form 4: Amneal Pharmaceuticals Executive Vice President Reports Stock Transactions
Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.